Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis

Huang, Jing-Juan; Ye, Sihua; Feng, Shaolan; Zheng, Minqi; Zhong, Meihua

doi:10.1007/s00384-023-04345-5

Cited by 4 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HFS prevalence in our study (all grades, 50.1%; grade ≥ 2, 14.6%) is consistent with previous ndings in other populations [7,9,10]. Despite urea cream being routinely prescribed for HFS at our centre and pharmacist counselling given, we still observed around 30% of the HFS cases worsened, and 20% required capecitabine treatment adjustments.…”

Section: Discussionsupporting

confidence: 91%

“…Moreover, 6% of them developed severe HFS. [10]. The study also highlighted disparities in HFS prevalence across different countries, with China having the highest rate at 55.1%, followed by Japan, Korea, and Italy [10].…”

Section: Introductionmentioning

confidence: 81%

“…[10]. The study also highlighted disparities in HFS prevalence across different countries, with China having the highest rate at 55.1%, followed by Japan, Korea, and Italy [10]. However, to our knowledge, no study has reported the HFS prevalence in the Malaysian population.…”

Section: Introductionmentioning

confidence: 82%

See 2 more Smart Citations

Hand-Foot Syndrome in Cancer Patients on Capecitabine: Examining Prevalence, Impacts, and Associated Risk Factors at a Cancer Centre in Malaysia

King,

Voon,

Yuen

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction Hand-foot syndrome (HFS) significantly impacts the quality of life in cancer patients undergoing capecitabine treatment. This study assessed capecitabine-associated HFS prevalence, its impacts on chemotherapy treatment, and identified risk factors in multiracial Malaysian patients. Methods We included adult cancer patients receiving capecitabine at Sarawak General Hospital for at least two cycles from April 1, 2021 to June 30, 2022. HFS rates, time to HFS, and proportions of HFS-related treatment modifications were determined. Characteristics between patients with and without HFS were compared and multivariable logistic regression was used to identify risk factors for all-grade HFS and grade ≥ 2. Results Among 369 patients, 185 (50.1%) developed HFS, with 14.6% experiencing grade ≥ 2. Notably, 21.6% of HFS cases underwent treatment modifications. Risk factors for all-grade HFS include older age (OR 1.04 95%CI 1.01, 1.06), prior chemotherapy (OR 2.12 95%CI 1.24, 3.61), higher capecitabine dose (OR 2.89 95%CI 1.69, 5.22), prolonged treatment (OR 1.34 95%CI 1.20, 1.49), and lower neutrophil count (OR 0.77 95%CI 0.66, 0.89). For HFS grade ≥ 2, older age (OR 1.04 95%CI 1.01, 1.08), female sex (OR 2.09 95%CI 1.05, 4.16), Chinese race (OR 2.07 95%CI 1.04, 4.10), and higher capecitabine dose (OR 2.61 95%CI 1.28, 5.32) are significant risk factors. Use of calcium channel blockers (OR 0.29, 95%CI 0.14, 0.59; OR 0.22 95%CI 0.66, 0.78) were associated with reduced risks of all-grade HFS and grade ≥ 2. Conclusion This study provides real-world data on capecitabine-induced HFS in Malaysian patients and identifies risk factors that may offer insights into its understanding and management.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 81%

See 1 more Smart Citation

Hand-Foot Syndrome in Cancer Patients on Capecitabine: Examining Prevalence, Impacts, and Associated Risk Factors at a Cancer Centre in Malaysia

King,

Voon,

Yuen

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Moreover, 6% of them developed severe HFS. [ 11 ]. The study also highlighted disparities in HFS prevalence across different countries, with China having the highest rate at 55.1%, followed by Japan, Korea, and Italy [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…[ 11 ]. The study also highlighted disparities in HFS prevalence across different countries, with China having the highest rate at 55.1%, followed by Japan, Korea, and Italy [ 11 ]. However, to our knowledge, no study has reported the HFS prevalence in the Malaysian population.…”

Section: Introductionmentioning

confidence: 99%

Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia

King,

Voon,

Yuen

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

Introduction Hand-foot syndrome (HFS) significantly impacts quality of life in cancer patients undergoing capecitabine treatment. This study assessed capecitabine-associated HFS prevalence, its impacts on chemotherapy treatment, and identified risk factors in multiracial Malaysian patients. Methods We included adult cancer patients receiving capecitabine at Sarawak General Hospital for at least two cycles from April 1, 2021 to June 30, 2022. HFS rates, time to HFS, and proportions of HFS-related treatment modifications were determined. Characteristics between patients with and without HFS were compared and multivariable logistic regression was used to identify risk factors for all-grade HFS and grade ≥2. Results Among 369 patients, 185 (50.1%) developed HFS, with 14.6% experiencing grade ≥2 and 21.6% (40/185) underwent treatment modifications. Risk factors for all-grade HFS include older age (OR 1.03 95%CI 1.01, 1.06), prior chemotherapy (OR 2.09 95%CI 1.22, 3.58), higher capecitabine dose (OR 2.96 95%CI 1.62, 5.38), prolonged treatment (OR 1.36 95%CI 1.21, 1.51), folic acid intake (OR 3.27 95%CI 1.45, 7.35) and lower neutrophil count (OR 0.77 95%CI 0.66, 0.89). For HFS grade ≥2, older age (OR 1.04 95%CI 1.01, 1.08), female sex (OR 2.10 95%CI 1.05, 4.18), Chinese race (OR 2.10 95%CI 1.06, 4.18), and higher capecitabine dose (OR 2.62 95%CI 1.28, 5.35) are significant risk factors. Use of calcium channel blockers were associated with reduced risks of all-grade HFS (OR 0.27, 95%CI 0.12, 0.60) and grade ≥2 (OR 0.21 95%CI 0.06, 0.78). Conclusion This study provides real-world data on capecitabine-induced HFS in Malaysian patients and identifies risk factors that may offer insights into its understanding and management.

show abstract

Chemotherapy-Induced Fingerprint Effacement Leading to Deprivation of Health Insurance: A Case Series and Review of Literature

Bansal,

Agrawal,

Mishra

et al. 2024

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PMJAY) is a game changer for the Indian health care system, where patients with cancer are the major beneficiaries. Some intrinsic procedural shortcomings are restricting the beneficiaries to utilize it optimally. We report a case series of patients receiving chemotherapy who had developed adermatoglyphia because of chemotherapeutic treatment. Therefore, these patients became ineligible for getting the benefits of PMJAY, because of failure of the biometric system to recognize their fingerprints. Hence, patient treatment could not be completed. As a solution, we suggest that the alternatives to fingerprint recognition like face recognition and iris scanning be incorporated into the biometric system to ensure continuous benefit of PMJAY to such patients.

show abstract

Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis

Cited by 4 publications

References 40 publications

Hand-Foot Syndrome in Cancer Patients on Capecitabine: Examining Prevalence, Impacts, and Associated Risk Factors at a Cancer Centre in Malaysia

Hand-Foot Syndrome in Cancer Patients on Capecitabine: Examining Prevalence, Impacts, and Associated Risk Factors at a Cancer Centre in Malaysia

Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia

Chemotherapy-Induced Fingerprint Effacement Leading to Deprivation of Health Insurance: A Case Series and Review of Literature

Contact Info

Product

Resources

About